$RLFTF DD (opinion) by OU3 on Yh0 The virus is mutating and will much more so once the Flu is prevalent again.
This is actually quite frightening but lab research has found that if the Influenza A combines with SARS-CoV-2 we have a very serious problem and treatments targeting ACE2 receptor are key.
Aviptadil could save countless lives and be incredibly valuable to have an impact on both Influenza and SARS-CoV-2.
“The upcoming flu season in the Northern Hemisphere merging with the current COVID-19 pandemic raises a potentially severe threat to public health.
Through experimental coinfection with influenza A virus (IAV) and either pseudotyped or live SARS-CoV-2 virus, we found that IAV preinfection significantly promoted the infectivity of SARS-CoV-2 in a broad range of cell types. Remarkably, in vivo, increased SARS-CoV-2 viral load and more severe lung damage were observed in mice coinfected with IAV.
Moreover, such enhancement of SARS-CoV-2 infectivity was not observed with several other respiratory viruses, likely due to a unique feature of IAV to elevate ACE2 expression.
This study illustrates that IAV has a unique ability to aggravate SARS-CoV-2 infection, and thus, prevention of IAV infection is of great significance during the COVID-19 pandemic.”
Go Aviptadil/Zyesami!
I am less concerned about our future knowing we have this drug so close to approval. See reply for citation link.
https://www.nature.com/articles/s41422-021-00473-1
This is actually quite frightening but lab research has found that if the Influenza A combines with SARS-CoV-2 we have a very serious problem and treatments targeting ACE2 receptor are key.
Aviptadil could save countless lives and be incredibly valuable to have an impact on both Influenza and SARS-CoV-2.
“The upcoming flu season in the Northern Hemisphere merging with the current COVID-19 pandemic raises a potentially severe threat to public health.
Through experimental coinfection with influenza A virus (IAV) and either pseudotyped or live SARS-CoV-2 virus, we found that IAV preinfection significantly promoted the infectivity of SARS-CoV-2 in a broad range of cell types. Remarkably, in vivo, increased SARS-CoV-2 viral load and more severe lung damage were observed in mice coinfected with IAV.
Moreover, such enhancement of SARS-CoV-2 infectivity was not observed with several other respiratory viruses, likely due to a unique feature of IAV to elevate ACE2 expression.
This study illustrates that IAV has a unique ability to aggravate SARS-CoV-2 infection, and thus, prevention of IAV infection is of great significance during the COVID-19 pandemic.”
Go Aviptadil/Zyesami!
I am less concerned about our future knowing we have this drug so close to approval. See reply for citation link.
https://www.nature.com/articles/s41422-021-00473-1
Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
